A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

摘要: Recently, we have reported a novel protocol for the generation of highly efficient cytotoxic effector cells by culturing PBLs in presence IFN-gamma, IL-2, mAb against CD3, and IL-1 alpha. We termed these cultures cytokine-induced killer (CIK) because phenotype with greatest cytotoxicity expresses both T cell marker CD3 NK CD56. Cells this are rare (approximately 1 to approximately 5%) uncultured PBLs. CD3+CD56+ expand nearly 1000-fold under culture conditions. The majority CIK were derived from CD3+CD56- cells, not CD3-CD56+ cells. Expression CD56, but CD8, on CD3+ correlated various cellular targets. used mice severe combined immunodeficiency (SCID) injected human lymphoma evaluate vivo antitumor effects vs lymphokine-activated (LAK) Groups animals inoculated x 10(6) SU-DHL4 (a B line t(14;18) chromosomal translocation), day later either i.v. or i.p., had significantly prolonged survival compared control tumor alone (median 90 days 58 days, p < 0.001) treated LAK 68 0.002). Approximately 30% SCID challenged became long-term survivors none No molecular evidence occult was found cell-treated when their bone marrow, spleen, liver, lung analyzed PCR at end 6 mo. By using conditions, population can be generated readily that superior activity mice, as